Trial
NCT01602120
An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Genentech, Inc.
Collaborators
—
Condition
Geographic Atrophy
Intervention
Lampalizumab
Why stopped
The study was terminated early by the Sponsor due to lack of efficacy.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-11